Clinical trials: Glucagon-Like Peptide-1 Receptor Agonists
Obesity
RESCUE: Discontinuation of GLP-1
This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
- Trial name
- NCT07190794
- Testing
- OverStitch™ or OverStitch NXT™, Lifestyle Modification
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Hormone-receptor-positive Breast Cancer, Early Breast Cancer
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1/GIP receptor agonist) affects breast cancer biology, alone and in combination with standard…
- Trial name
- CLARA (NCT07676331)
- Testing
- Tirzepatide, Letrozole (Aromatase Inhibitors)
- Volunteers
- 168 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Non-alcoholic Fatty Liver Disease
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in…
- Trial name
- LIGHT-ON (NCT02147925)
- Testing
- Liraglutide combined with metformin, Insulin glargine combined with metformin, Sitagliptin combined with metformin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Dietary Change, Obesity & Overweight
Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy
In this study will look at how eating pistachios every day might affect participants weight, how healthy their diet is, and how they feel when eating.
- Conditions
- Dietary Change, Obesity & Overweight, Food Acceptance
- Trial name
- NCT07244445
- Testing
- Pistachios, Dual-energy X-ray absorptiometry (DEXA) scans
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Ian J. Neeland, MD
Type 2 Diabetes
Pharmacogenomics of GLP1 Receptor Agonists
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility.
- Trial name
- NCT05762744
- Testing
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
The investigators plan to enroll 60 patients from the outpatient clinics or inpatient wards of the Metabolism and Cardiology departments who, within the past three months, have undergone coronary angiography for the treatment of…
- Conditions
- Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes, Coronary Arterial Disease (CAD)
- Trial name
- NCT07073053
- Testing
- Semaglutide 1.0 mg, Semaglutide 0.5 mg
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Obesity, Diabetes
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Glucagon-like peptide-1 (GLP-1) receptor agonist are new treatment of type 2 diabetes, they lower blood glucose level (by enhancement of glucose-dependent insulin secretion and suppression of excess glucagon secretion) and reduce…
- Trial name
- NCT02042664
- Testing
- BYETTA treatment, Metformine
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Diabetes Mellitus, Type 2, Anesthesia
Investigation of the Evolution of Gastric Emptying by Gastric Ultra Sonography in Patients Treated With GLP-1 Receptor Agonists on a 7 Days Pausing Period.
Glucagon-like-peptide-1 is a hormone released by the gut enteroendocrine cells. Its secretion occurs after each meal to enable production of insulin and inhibits the production of glucagon to lower after meal glycemia.
- Conditions
- Diabetes Mellitus, Type 2, Anesthesia, Pulmonary Aspiration of Gastric Contents
- Trial name
- NCT06388213
- Testing
- Gastric Ultrasonography
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Food Addiction Tendency, Obesity
Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies
The goal of this clinical trial is to investigate how semaglutide affects the way the brain responds to food in adults with obesity and food addiction tendencies.
- Conditions
- Food Addiction Tendency, Obesity, Overweight
- Trial name
- NCT07732426
- Testing
- Semaglutide
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital